SVA - Week In Review: Akeso Stages $335 Million HK IPO For Mono-/Bi-Specific Antibodies
Deals and Financings
AkesoBio [HK:9926], a Zhongshan developer of novel mono- and bi-specific antibodies, staged a $335 million Hong Kong IPO and climbed 50% higher in its first trading session. The company's general strategy is to develop bispecific antibodies using a PD-1 antibody as a backbone. It has built a portfolio of 18 mAbs that are in either CMC or clinical stages of development. Last year, Akeso formed a $100 million JV with a Sino Biopharm [HK:1177] subsidiary to develop and commercialize AK105, its clinical-stage anti-PD-1 mAb.
Hansoh [HK:3692], a Shanghai Pharma, in-licensed Greater China